242 related articles for article (PubMed ID: 18621681)
1. Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain.
Mast N; White MA; Bjorkhem I; Johnson EF; Stout CD; Pikuleva IA
Proc Natl Acad Sci U S A; 2008 Jul; 105(28):9546-51. PubMed ID: 18621681
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain.
Mast N; Charvet C; Pikuleva IA; Stout CD
J Biol Chem; 2010 Oct; 285(41):31783-95. PubMed ID: 20667828
[TBL] [Abstract][Full Text] [Related]
3. In silico and intuitive predictions of CYP46A1 inhibition by marketed drugs with subsequent enzyme crystallization in complex with fluvoxamine.
Mast N; Linger M; Clark M; Wiseman J; Stout CD; Pikuleva IA
Mol Pharmacol; 2012 Nov; 82(5):824-34. PubMed ID: 22859721
[TBL] [Abstract][Full Text] [Related]
4. The antifungal drug voriconazole is an efficient inhibitor of brain cholesterol 24S-hydroxylase in vitro and in vivo.
Shafaati M; Mast N; Beck O; Nayef R; Heo GY; Björkhem-Bergman L; Lütjohann D; Björkhem I; Pikuleva IA
J Lipid Res; 2010 Feb; 51(2):318-23. PubMed ID: 19474457
[TBL] [Abstract][Full Text] [Related]
5. Antifungal Azoles: Structural Insights into Undesired Tight Binding to Cholesterol-Metabolizing CYP46A1.
Mast N; Zheng W; Stout CD; Pikuleva IA
Mol Pharmacol; 2013 Jul; 84(1):86-94. PubMed ID: 23604141
[TBL] [Abstract][Full Text] [Related]
6. Combined use of mass spectrometry and heterologous expression for identification of membrane-interacting peptides in cytochrome P450 46A1 and NADPH-cytochrome P450 oxidoreductase.
Mast N; Liao WL; Pikuleva IA; Turko IV
Arch Biochem Biophys; 2009 Mar; 483(1):81-9. PubMed ID: 19161969
[TBL] [Abstract][Full Text] [Related]
7. Steroid and protein ligand binding to cytochrome P450 46A1 as assessed by hydrogen-deuterium exchange and mass spectrometry.
Liao WL; Dodder NG; Mast N; Pikuleva IA; Turko IV
Biochemistry; 2009 May; 48(19):4150-8. PubMed ID: 19317426
[TBL] [Abstract][Full Text] [Related]
8.
Mast N; Anderson KW; Johnson KM; Phan TTN; Guengerich FP; Pikuleva IA
J Biol Chem; 2017 Aug; 292(31):12934-12946. PubMed ID: 28642370
[TBL] [Abstract][Full Text] [Related]
9. Binding of a cyano- and fluoro-containing drug bicalutamide to cytochrome P450 46A1: unusual features and spectral response.
Mast N; Zheng W; Stout CD; Pikuleva IA
J Biol Chem; 2013 Feb; 288(7):4613-24. PubMed ID: 23288837
[TBL] [Abstract][Full Text] [Related]
10. Mapping of the Allosteric Site in Cholesterol Hydroxylase CYP46A1 for Efavirenz, a Drug That Stimulates Enzyme Activity.
Anderson KW; Mast N; Hudgens JW; Lin JB; Turko IV; Pikuleva IA
J Biol Chem; 2016 May; 291(22):11876-86. PubMed ID: 27056331
[TBL] [Abstract][Full Text] [Related]
11. Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain.
Mast N; Norcross R; Andersson U; Shou M; Nakayama K; Bjorkhem I; Pikuleva IA
Biochemistry; 2003 Dec; 42(48):14284-92. PubMed ID: 14640697
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice.
Mast N; Li Y; Linger M; Clark M; Wiseman J; Pikuleva IA
J Biol Chem; 2014 Feb; 289(6):3529-38. PubMed ID: 24352658
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Dicaffeoylspermidine Derivatives from Wolfberry as Potent and Selective Inhibitors of Human Cytochrome P450 46A1
Du J; Liu J; Wang S; Wang C; Meng Q; Sun H; Liu K; Liu Y; Wu J
Curr Drug Metab; 2023; 24(2):124-130. PubMed ID: 36748817
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
Mast N; Verwilst P; Wilkey CJ; Guengerich FP; Pikuleva IA
J Med Chem; 2020 Jun; 63(12):6477-6488. PubMed ID: 31617715
[TBL] [Abstract][Full Text] [Related]
15. Transcription of cytochrome P450 46A1 in NIH3T3 cells is negatively regulated by FBS.
Shinohara Y; Ando H; Maekawa M; Arai M; Horibata Y; Satou M; Jojima T; Usui I; Aso Y; Sugimoto H
Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Jun; 1867(6):159136. PubMed ID: 35306146
[TBL] [Abstract][Full Text] [Related]
16. CYP46A1-dependent and independent effects of efavirenz treatment.
Mast N; El-Darzi N; Petrov AM; Li Y; Pikuleva IA
Brain Commun; 2020; 2(2):fcaa180. PubMed ID: 33305262
[TBL] [Abstract][Full Text] [Related]
17. Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases.
Petrov AM; Pikuleva IA
Neurotherapeutics; 2019 Jul; 16(3):635-648. PubMed ID: 31001737
[TBL] [Abstract][Full Text] [Related]
18. 24S-hydroxycholesterol and cholesterol-24S-hydroxylase (CYP46A1) in the retina: from cholesterol homeostasis to pathophysiology of glaucoma.
Fourgeux C; Bron A; Acar N; Creuzot-Garcher C; Bretillon L
Chem Phys Lipids; 2011 Sep; 164(6):496-9. PubMed ID: 21531213
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional and post-translational changes in the brain of mice deficient in cholesterol removal mediated by cytochrome P450 46A1 (CYP46A1).
Mast N; Lin JB; Anderson KW; Bjorkhem I; Pikuleva IA
PLoS One; 2017; 12(10):e0187168. PubMed ID: 29073233
[TBL] [Abstract][Full Text] [Related]
20. Cholesterol-24S-hydroxylase (CYP46A1) is specifically expressed in neurons of the neural retina.
Bretillon L; Diczfalusy U; Björkhem I; Maire MA; Martine L; Joffre C; Acar N; Bron A; Creuzot-Garcher C
Curr Eye Res; 2007 Apr; 32(4):361-6. PubMed ID: 17453958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
